<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829385</url>
  </required_header>
  <id_info>
    <org_study_id>LZU-123</org_study_id>
    <nct_id>NCT02829385</nct_id>
  </id_info>
  <brief_title>Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients</brief_title>
  <official_title>A Phase II Clinical Trial Study on Apatinib and XELOX Combination Regimen in the First-line Treatment of End-stage Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shoucheng Ma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LanZhou University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study makes an observation over the objective response rate of Apatinib and XELOX
      combination regimen in the first-line treatment of metastatic colorectal cancer. All the
      participants will receive the treatment of Apatinib and XELOX combination regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      XELOX chemotherapy is an effective therapy for metastatic colorectal cancer as first-line
      treatment.

      Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to
      and strongly inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), with a
      decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular
      density. A phase II trail of Apatinib has been demonstrated that Apatinib is safe to treat
      the metastatic colorectal cancer and the disease control rate can reach 50%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 9 months</time_frame>
    <description>ORR=complete response (CR) + partial response (PR) .And expected ORR is 0.55.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>time from randomization to documented progressive disease or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Apatinib combined treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)
Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib and XELOX combined treatment group</intervention_name>
    <description>Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)
Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs.</description>
    <arm_group_label>Apatinib combined treatment group</arm_group_label>
    <other_name>Apatinib combined treatment group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unresectable colorectal cancer confirmed by histological means with measurable
             indication（a minimum size of 10mm by spiral CT scan，which meets the criteria of RECIST
             1.1）.

          -  Time interval traced back to the latest administration of xelox and folfox combination
             must be no less than 1 year.

          -  age range: ≥18 and ≤75.

          -  ECOG PS scale 0 or 1；expected survival time ≥12 weeks.

          -  Sufficient blood function：absolute neutrophil count (ANC) ≥1.5×109/L, platelet count
             ≥80×109/L and hemoglobin≥9g/dL.

          -  Sufficient hepatic function：total bilirubin ≤1.5 times upper normal limit(ULN), AST
             ≤2.5 times ULN, ALT ≤2.5 times ULN and AKP ≤5 times ULN.

             *AST,ALT relevant criteria alters into AST ≤5 times ULN and ALT ≤5 times ULN if with
             hepatic metastasis.

          -  sufficient renal function: serum creatinin ≤ULN, creatinine clearance rate ≥60 mL/min

          -  Female patients under age 50 with complete uterus must be tested negative for
             pregnancy within 28 days before enrollment (except for those who suffered amenorrhea
             for more than 24 months). If the pregnancy test was carried out more than 7 days
             before the first administration, then the urine pregnancy test is required for
             validation. (within the 7-day interval before administration)

          -  Informed consent subscription. (The consent should be approved by independent Ethics
             Committee, and signed by patients before any substantial trial is initiated.)

        Exclusion Criteria:

          -  Have got other malignant tumors within last 5 years, excluding basal cell skin cancer
             and cervical carcinoma in situ that has already been cured.

          -  With evidence of CNS metastasis, even if the treatment had been carried out before,
             patients with doubts of CNS metastasis should be conducted MRI or enhanced CT scan on
             within 28 days before enrollment for ruling out.

          -  AST ≤2.5 times ULN and/or ALT ≤2.5 times ULN

          -  Had been treated with chemotherapy for last 12 months

          -  Had been treated with radiotherapy (except for palliative radiotherapy with evaluable
             focus outside radiotherapy field on purpose of alleviating pains)

          -  With any uncontrolled systemic disease, including active infection, hypertension
             without treatment, diabetes mellitus, angina pectoris, congestive heart failure,
             myocardial infarction, severe arrhythmia requires treatment and
             hepatic/renal/metabolic diseases

          -  Taking experimental treatment from another clinical trial study.

          -  Being allergic to any relevant chemotherapy drug.

          -  With evidence-proved other diseases, neural or metabolic disorders, physical or lab
             examination abnormalities, which might be contraindication of study drugs or leading
             to treating-related lethal complications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Da Zhao, Bachelor</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Center of the First Hospital of Lanzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shoucheng Ma, Master</last_name>
    <phone>(86)13893453504</phone>
    <email>mashoucheng@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Cnter,The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shoucheng Ma, Master</last_name>
      <phone>(86)13893453504</phone>
      <email>mashoucheng@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016 May 1;34(13):1448-54. doi: 10.1200/JCO.2015.63.5995. Epub 2016 Feb 16.</citation>
    <PMID>26884585</PMID>
  </results_reference>
  <results_reference>
    <citation>Tabernero J, Van Cutsem E, Lakomý R, Prausová J, Ruff P, van Hazel GA, Moiseyenko VM, Ferry DR, McKendrick JJ, Soussan-Lazard K, Chevalier S, Allegra CJ. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014 Jan;50(2):320-31. doi: 10.1016/j.ejca.2013.09.013. Epub 2013 Oct 16.</citation>
    <PMID>24140268</PMID>
  </results_reference>
  <results_reference>
    <citation>Kara O, Duman BB, Kara B, Erdogan S, Parsak CK, Sakman G. Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy. Asian Pac J Cancer Prev. 2012;13(12):6397-401.</citation>
    <PMID>23464465</PMID>
  </results_reference>
  <results_reference>
    <citation>Custodio A, Barriuso J, de Castro J, Martínez-Marín V, Moreno V, Rodríguez-Salas N, Feliu J. Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives. Cancer Treat Rev. 2013 Dec;39(8):908-24. doi: 10.1016/j.ctrv.2013.02.004. Epub 2013 Mar 16. Review.</citation>
    <PMID>23510598</PMID>
  </results_reference>
  <results_reference>
    <citation>Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E. Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients. Biomed Res Int. 2013;2013:143273. doi: 10.1155/2013/143273. Epub 2013 Nov 6.</citation>
    <PMID>24307987</PMID>
  </results_reference>
  <results_reference>
    <citation>Sclafani F, Cunningham D. Bevacizumab in elderly patients with metastatic colorectal cancer. J Geriatr Oncol. 2014 Jan;5(1):78-88. doi: 10.1016/j.jgo.2013.08.006. Epub 2013 Sep 20. Review.</citation>
    <PMID>24484722</PMID>
  </results_reference>
  <results_reference>
    <citation>Naeim A, Ward PR, Wang HJ, Dichmann R, Liem AK, Chan D, Patel R, Hu EH, Tchekmedyian NS, Wainberg ZA, Hecht JR. A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer. J Geriatr Oncol. 2013 Oct;4(4):302-9. doi: 10.1016/j.jgo.2013.05.001. Epub 2013 Jun 7.</citation>
    <PMID>24472472</PMID>
  </results_reference>
  <results_reference>
    <citation>Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015 May 9;385(9980):1843-52. doi: 10.1016/S0140-6736(14)62004-3. Epub 2015 Apr 7.</citation>
    <PMID>25862517</PMID>
  </results_reference>
  <results_reference>
    <citation>Kiss I, Bortlicek Z, Melichar B, Poprach A, Halamkova J, Vyzula R, Dusek L, Buchler T. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma. Anticancer Res. 2014 Feb;34(2):949-54.</citation>
    <PMID>24511038</PMID>
  </results_reference>
  <results_reference>
    <citation>Kishiki T, Ohnishi H, Masaki T, Ohtsuka K, Ohkura Y, Furuse J, Watanabe T, Sugiyama M. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS. Cancer Chemother Pharmacol. 2014 Apr;73(4):749-57. doi: 10.1007/s00280-014-2401-4. Epub 2014 Feb 6.</citation>
    <PMID>24500024</PMID>
  </results_reference>
  <results_reference>
    <citation>Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, He P, Yu H, Koukakis R, Terwey JH, Jung AS, Sidhu R, Patterson SD. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clin Cancer Res. 2015 Dec 15;21(24):5469-79. doi: 10.1158/1078-0432.CCR-15-0526. Epub 2015 Sep 4.</citation>
    <PMID>26341920</PMID>
  </results_reference>
  <results_reference>
    <citation>Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275.</citation>
    <PMID>24024839</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>LanZhou University</investigator_affiliation>
    <investigator_full_name>Shoucheng Ma</investigator_full_name>
    <investigator_title>director of cancer center</investigator_title>
  </responsible_party>
  <keyword>Apatinib</keyword>
  <keyword>XELOX Regimen</keyword>
  <keyword>metastatic colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

